Leukemia, Myelodysplasia, Transplantation

News

Treatment of CML continues to progress

Dr O’Brien listed standard-dose imatinib, high-dose imatinib, imatinib-based combinations, second generation tyrosine kinase inhibitors (TKIs) and...

Pages